Clinical Trial

Digital and Plasma Biomarkers in Delirium

Study acronym: DELTA
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn if there are potential digital and plasma-based biomarkers that could help detect, predict, and prognosticate delirium in older adult patients who are admitted to the intensive care unit (ICU). The main question DELTA aims to answer is: Can digital biometrics predict and detect delirium in older adult ICU patients? Do biomarkers of neurodegeneration fluctuate in ICU patients in such a way that delrium could potentially be predicted? Participants admitted o the ICU will wear a digital device to collect biometric data and will have serial plasma samples collected during ICU admission and patients will be also assessed for delirium daily by study staff.
Trial Details
NCT Number NCT07694206
Lead Sponsor Scripps Health
Conditions Critical Illness, Delirium in the Intensive Care Unit, Sleep Quality
Enrollment 100 participants
Start Date 2026-05-28
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-09